Search Results

Displaying Results 1-2 of 2 "'BDTX'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight

Jun 15, 2026, 12:31 ET EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight

(BMS-986507), Telisotuzumab Adizutecan (Temab-A/ABB-400), LP-300, WSD0922-FU, Sutetinib, Quaratusugene ozeplasmid (REQORSA), JIN-A02, Silevertinib, (BDTX-1535), BH-30643, STX-241/PFL-241, STX-721/PFL-271, A2B395, BNT326 (YL 202), DF9001, Pamvatamig (MCLA-129), TAS3351, DB-1310, Enozertinib (ORIC-114 ), BG-60366,

More news about: DelveInsight Business Research, LLP

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

Pharma, CSPC Pharmaceutical (HKG: 1093), AbbVie (NYSE: ABBV), Teligene, Bristol–Myers Squibb (NYSE: BMY), SystImmune, Black Diamond Therapeutics (NASDAQ: BDTX), Lantern Pharma (NASDAQ: LTRN), and others, are developing new EGFR-NSCLC treatment drugs that can be available in the EGFR-NSCLC market in the

More news about: DelveInsight Business Research, LLP

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.